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Abstract
RanBPM/RanBP9 is a multi-domain nucleocytoplasmic protein which has
been linked to numerous cellular processes including cell adhesion, migration,
transcription and apoptosis. Although RanBPM is a member of the mammalian
CTLH complex, the counterpart of a conserved yeast E3 ubiquitin ligase complex, its
exact function remains unknown. Previous work in our laboratory has shown that
RanBPM inhibits the ERK pathway by interacting with the kinase c-Raf and
downregulating c-Raf levels. Here, we show that the N-terminus, LisH/CTLH and
CRA domains of RanBPM are required for downregulation of c-Raf and that
RanBPM interacts directly with c-Raf through its CRA domain. We also provide
evidence that MAEA, another CTLH complex member, associates with c-Raf.
Therefore, we propose a mechanism by which RanBPM downregulates c-Raf in a
CTLH complex-dependent manner. This work contributes to our knowledge of the
function of RanBPM and clarifies the relationship between RanBPM and c-Raf, two
important proteins in oncogenesis.
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Chapter 1 – Introduction
1.1. Cancer
According to the Canadian Cancer Society, it is estimated that
approximately 267,400 Canadians will be diagnosed with cancer in 2014, with
the most common types being prostate, breast, lung, colorectal and nonmelanoma skin cancer (1). Cancer is the leading cause of death in Canada, with
an estimated 1 in 4 Canadians expected to die from the disease (1). Therefore, it
is evident that cancer research focused on understanding the disease and
developing new treatments to combat tumour growth are of utmost importance to
preserve the health of our population.
Although the average one gram malignant tumour is estimated to contain
108–109 cancer cells, such tumour masses can start with the defiant behaviour of
a single cell (2). Cells are programmed to grow, replicate and die when they have
reached the end of their lifespan, however a cell can break free from these
restraints in the event of genomic mutation and proliferate uncontrollably,
resulting in cellular transformation and tumourigenesis. Cancer cells exhibit
certain characteristics, termed the hallmarks of cancer, which are acquired during
cellular transformation and are predominantly responsible for the progression of
the disease (3). Namely, they sustain proliferative signaling, evade signaling from
growth suppressors, resist cell death, replicate infinitely, induce angiogenesis
and invade surrounding tissues (3).
Understanding the cellular and molecular processes behind each of these
hallmarks is key in understanding how a healthy cell transforms into a malignant
cell, and ultimately contributes valuable knowledge that can be used to generate
novel therapies to fight cancer. This thesis aims to contribute to this pool of
knowledge by studying the relationship between RanBPM (Ran-binding protein
M) and c-Raf (rapidly accelerating fibrosarcoma), two proteins known to play
roles in critical cellular processes which, when perturbed, can lead to the
development of the hallmarks of cancer.
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1.2. RanBPM

1.2.1. Overview of RanBPM
RanBPM, also known as RanBP9, was initially discovered in a yeast twohybrid assay as a 55kDa interacting partner for the small guanosine
triphosphatase (GTPase), Ran (Ras-related nuclear protein) (4). However,
subsequent studies soon uncovered that RanBPM is in fact a 90kDa protein, only
weakly interacts with Ran and does not localize to the centrosome, as initially
thought (4,5). Since then, RanBPM has generated significant interest and
numerous studies have been conducted on the protein to attempt to characterize
its function.
RanBPM is widely conserved across mammals, with over 96% similarity
between human and mouse RanBPM, although homologs are also present in
many other species (6). In mammals, RanBPM has been shown to be
ubiquitously expressed, with higher expression in heart, muscle, brain and
reproductive tissues (7,8). RanBPM was initially recovered in a 670kDa complex
and, since then, its involvement in complex formation has been described
extensively (5,9). It has been shown to interact with countless proteins and be
implicated in a variety of cellular processes including, but not limited to,
transcription, cell adhesion, cell migration and apoptosis (9). Although a
considerable number of studies have identified proteins that interact with
RanBPM (Table 1.1), a large portion of them lack insight on the functional
significance of the interactions (9). For these reasons, RanBPM has widely been
hypothesized to be a scaffolding protein, however, its exact function still remains
unknown (9).
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Table 1.1. Comprehensive list of proteins that have been shown to interact
with RanBPM. Methods used to demonstrate the interactions are indicated as yeast
two-hybrid

(Y2H),

mammalian

two-hybrid

(M2H),

pull-down

(PD),

immunoprecipitation (IP), proximity ligation assay (PLA), confocal microscopy (CM)
and/or fluorescence resonance energy transfer (FRET).

Methods

Domains of
RanBPM required

References

IP

ND

(13)

Y2H, PD, IP

ND

(17)

CDK11

Y2H, PD, IP, CM

SPRY

(20)

p75NTR

Y2H, IP

ND

(21)

HIPK2

Y2H, IP, CM

ND

(22)

c-Raf

PD, IP, PLA

CRA

(24), present study

L1

Y2H, PD, IP

SPRY

(25)

MET

Y2H, M2H, PD, IP

SPRY

(8)

TrkB

IP, CM

ND

(26)

APP

IP

SPRY/LisH

(29)

BACE1

IP

SPRY/LisH

(29)

LRP

IP

SPRY/LisH

(29)

Y2H, PD, IP, CM

CRA

(14)

Y2H, IP

ND

(34)

TrkA

Y2H, PD, IP

SPRY

(35)

TAF4

Y2H, IP, CM

ND

(36)

AR

Y2H, PD, IP

SPRY

(7)

TR

Y2H, PD, IP

ND

(37)

LFA-1

Y2H, PD, IP

ND

(39)

Y2H, IP

ND

(39)

BLT-2

Y2H, PD, IP, CM

ND

(43)

BRCA1

Y2H

ND

(44)

Y2H, IP

ND

(42,46)

Y2H, IP, PD

ND

(42,46)

Rmnd5a

IP

ND

(46)

MAEA

IP

ND

(46)

ARMc8

IP

ND

(46)

HDAC6

IP, CM

LisH/CTLH

(103)

TRAF6

Y2H, PD, IP, CM, FRET

ND

(107)

USP11

Y2H, IP

SPRY

(109)

Interacting proteins
RanBPM
p73
p46

FMRP
plexin-A

β1 integrin

Muskelin
Twa1
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1.2.2. Conserved domains
Four conserved functional domains have been identified within the
sequence of RanBPM: the SplA and Ryanodine receptor (SPRY) domain, the
Lissencephaly type-1-like homology (LisH) domain, the C-terminal to LisH
(CTLH) domain and the CT11-RanBPM (CRA) domain (Figure 1.1) (10). The
SPRY domain is known to be involved in protein-protein interactions (11). The
LisH domain is known to mediate protein dimerization, and is in fact predicted to
moderate the dimerization and oligomerization of RanBPM (12,13). Additionally,
the LisH domain, together with the CTLH domain, is thought to regulate
microtubule dynamics and cell migration (12). The CRA domain, which is
predicted to contain six α-helices and resembles a death domain (DD)
superfamily domain, has also been shown to function as a protein interaction
surface (14). In addition to these four conserved domains, RanBPM also contains
a proline- and glutamine-rich N-terminus predicted to contain six Src homology 3
(SH3) binding domains (5,15).
1.2.3. Cellular localization
Although RanBPM was initially thought to be localized to the centrosome,
further studies determined its localization to actually be predominantly
nucleocytoplasmic (4,5). Recent studies in our laboratory have identified a
primary nuclear localization signal (NLS) spanning amino acids 1–25, a
secondary NLS spanning amino acids 635–649 and a nuclear export signal
(NES) comprising amino acids 140–155, which together govern the subcellular
localization of RanBPM (16). The SPRY and LisH/CLTH domains were also
shown to be important for cytoplasmic retention of RanBPM, potentially through
interactions with cytoplasmic proteins (16).
Indeed, the subcellular localization of RanBPM has previously been
shown to be influenced by interactions with other proteins. For example,
overexpression of p73 was shown to promote the translocation of RanBPM from

4

Figure 1.1. Full-length RanBPM with conserved domains indicated. RanBPM
contains a SPRY domain (amino acids 212–333), a LisH/CTLH domain (amino acids
367–460) and a CRA domain (amino acids 615–729).
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the cytoplasm to the nucleus (17). Given that these two proteins physically
interact and p73 is exclusively nuclear, it was hypothesized that an
overabundance of p73 could sequester a high proportion of cellular RanBPM in
the nucleus (17). Furthermore, under certain cellular conditions, RanBPM
localization has been reported to be altered. For example, in response to ionizing
radiation (IR), a DNA damage-inducing agent, RanBPM has been shown to
shuttle from the nucleus to the cytoplasm (18). This change in localization could
occur to allow RanBPM to interact with cytoplasmic apoptotic or DNA damage
response proteins, although this speculation has yet to be confirmed (18).
Altogether, such evidence suggests that RanBPM localization is important in
dictating its function, as it allows RanBPM to interact with various specifically
compartmentalized proteins and participate in different signaling pathways.
1.2.4. Role in apoptosis
Although the specific function of RanBPM has yet to be elucidated, there
is substantial evidence that it plays an important role in the activation of
apoptosis. RanBPM has been shown to interact with the tumour-suppressor
protein p73 and enhance its apoptotic activity (17). The interaction between
these two proteins was demonstrated to be required for the ability of RanBPM to
activate apoptosis, induce mitochondrial membrane permeability, decrease levels
of the anti-apoptotic protein Bcl-2 (B cell lymphoma 2), increase levels of the proapoptotic protein Bax and enhance Bax oligomerization (19). It has also been
demonstrated that, through its SPRY domain, RanBPM interacts with and is
phosphorylated by CDK11p46 (cyclin-dependent kinase 11), a caspase-cleaved
C-terminal kinase segment of the larger CDK11p110 isoform (20). Caspasecleavage of CDK11p110 occurs during apoptosis and cleaved CDK11p46 continues
to propagate apoptotic signals, potentially through a RanBPM-dependent
mechanism (20). RanBPM has also been shown to interact with the pro-apoptotic
neurotrophin receptor p75NTR (p75

neurotrophin

receptor) through

its

intracellular DD and to interact with the nuclear protein kinase HIPK2
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(homeodomain-interacting protein kinase 2), which has been shown to activate
and stabilize the tumour-suppressor protein p53 (21-23).
Important studies in our laboratory have demonstrated that RanBPM
activates apoptosis in response to DNA damage caused by IR (18). Subsequent
studies showed that RanBPM is in fact an inhibitor of the ERK (extracellular
signal-regulated kinase) pathway and specifically downregulates the crucial ERK
pathway kinase c-Raf at the protein level (24). This resulted in decreased
downstream ERK pathway signaling, culminating in decreased levels of the antiapoptotic protein Bcl-2 and its family member Bcl-XL (B cell lymphoma extra
large) (24). This is consistent with previous findings that RanBPM regulates the
intrinsic cell death pathway (19). In addition, it was found that downregulation of
RanBPM leads to increased cell proliferation, an important hallmark of cellular
transformation and cancer (24).
Other studies have also shown that RanBPM restricts ERK pathway
signaling. For example, through its SPRY domain, it was observed that an Nterminal fragment of RanBPM interacts with the neural adhesion molecule L1 to
inhibit downstream ERK signaling (25). Although it appears that RanBPM is a
pro-apoptotic protein that inhibits the ERK pathway, there is some opposing
evidence that RanBPM activates the ERK pathway through interactions with the
receptor tyrosine kinases TrkB (tropomyosin-related kinase B) and MET
(mesenchymal epithelial transition factor), although the latter was shown using a
green fluorescent protein (GFP) tagged RanBPM construct (8,26). Therefore,
some of the contradiction regarding RanBPM regulation of the ERK pathway
could potentially be attributed to the different constructs used in each study and
the unknown effects of large tags or truncations on the overall function of
RanBPM.
1.2.5. Functions in the reproductive and nervous systems
Numerous studies have demonstrated roles for RanBPM in the
reproductive and nervous systems, but nowhere is this more evident than in the

7

characterization of RanBPM knockout mice. It is well documented that RanBPM
knockout mice generally die neonatally, although a small number of newborn
pups have been reported to survive into adulthood (27,28). The cause of this
neonatal fatality remains unclear, although it has been suggested that these pups
are unable to suckle milk, suggesting defects in brain function (28). RanBPM
knockout mice suffer pronounced gonadal atrophy, severely compromised
spermatogenesis and oogenesis as well as infertility, provided they reach
adulthood (27). Furthermore, they display growth retardation and their brains are
dramatically reduced in size, especially in the hippocampal and cortical regions,
compared to wild-type (WT) mice (28).
A number of important studies have also implicated RanBPM in the
development of the neurodegenerative disorder Alzheimer’s disease (AD).
Interestingly, a truncated form of RanBPM has been shown to be expressed over
six times higher in the brains of AD patients compared to those of healthy
individuals (13). One of the defining pathological hallmarks of AD is the
accumulation of Aβ (amyloid β) peptides in the brain and RanBPM has been
shown to promote Aβ generation from its precursor APP (amyloid precursor
protein) (29). RanBPM accelerates endocytosis of APP and acts as a scaffold for
APP, BACE1 (β-secretase 1) and the endocytosis receptor LRP (low-density
lipoprotein receptor-related protein) to facilitate BACE1 cleavage of APP into Aβ
(29). Consistent with previously mentioned evidence regarding RanBPM
involvement

in

apoptosis,

these

studies

have

shown

that

RanBPM

overexpression causes apoptosis and also potentiates Aβ toxicity in the brain
(30). In addition, RanBPM transgenic mice suffered neurodegeneration, spatial
memory loss and a decreased number of neuronal synapses (31).
RanBPM has been shown to interact with proteins involved in other
neurodegenerative diseases as well. RanBPM interacts with FMRP, a protein
whose loss of expression leads to the most common form of hereditary mental
retardation, fragile X syndrome (32). FMRP is an RNA-binding protein
predominantly found in neurons and spermatogonia that regulates translation
and transport of mRNA (32,33). Through its CRA domain, RanBPM directly binds
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and sequesters the RNA-binding region of FMRP, rendering it unable to execute
its RNA-binding function (14). RanBPM has also been reported to interact with
the neural adhesion molecule L1, which can lead to various X-linked disorders if
mutated (9). Inhibition of ERK signaling by an N-terminal fragment of RanBPM
suppresses L1-meditated neurite outgrowth and branching in primary neurons
(25).
Further functions for RanBPM in the nervous system include interaction
with the plexin-A receptor to inhibit axonal outgrowth and induce neuronal
contractility (34). RanBPM also been shown to interact with the receptor tyrosine
kinases TrkB and TrkA, which both serve as neurotrophin receptors in the brain
(26,35). Through its interaction with TrkB, RanBPM was shown to enhance
neuronal morphogenesis, and through its interaction with TrkA, RanBPM was
shown to reduce downstream expression of the transcription factor NFAT
(nuclear factor of activated T cells), which is known to play a role in axon
outgrowth and synaptic plasticity (26,35).
1.2.6. Regulation of transcriptional activity
RanBPM has further been suggested to regulate transcriptional activity in
the cell. RanBPM has been shown to interact with TAF4 (transcription initiation
factor TFIID subunit 4), a subunit of the general transcription factor TFIID
(transcription factor II D) (36). TFIID is a member of the RNA polymerase II
preinitation complex that binds the TATA box during the initial steps of gene
transcription. The interaction between RanBPM and TAF4 was demonstrated to
initiate primary neurite branching in neuronal stem cells, although the
transcriptional model by which this occurs has yet to be elucidated (36).
Furthermore, RanBPM has been reported to interact with the ligand-dependent
transcription factors AR (androgen receptor) and TR (thyroid hormone receptor)
and enhance their transcriptional activities (7,37). RanBPM can also augment the
transcriptional activity of GR (glucocorticoid receptor), although an interaction
between the two proteins has not explicitly been shown (7).
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Microarray analyses in our laboratory have shown that RanBPM
influences transcriptional pathways primarily associated with cell, tissue and
organ development as well as tumorigenesis and cancer (38). Upon RanBPM
downregulation, global gene expression changes occurred and over-represented
transcription factor binding sites were identified among the upregulated or
downregulated genes (38). Among the most over-represented were binding sites
for the Forkhead, homeodomain and HMG (high mobility group) transcription
factors, providing further evidence that RanBPM regulates transcription by
modulating transcription factor activity (38).
1.2.7. Implications in cell morphology, adhesion and migration
There is evidence of RanBPM involvement in cell morphology and polarity,
based on its reported interactions with known regulators of these processes. It
has been reported that RanBPM interacts with β1 integrin and the β2 integrin
LFA-1

(lymphocyte

function-associated

antigen-1)

(39,40).

Integrins

are

transmembrane receptors that are well-known for mediating cell-cell and cellextracellular matrix interactions through focal adhesions, however, they also
participate in many signaling pathways within the cell (39). RanBPM has been
shown to accelerate endocytosis of β1 integrin to disrupt integrin-dependent cell
adhesion, focal adhesion assembly and focal adhesion signaling (40). Some data
also suggests that RanBPM acts in conjunction with Muskelin to regulate cell
morphology and cell spreading, as they are found together in a complex and
knockdown of either Muskelin or RanBPM in lung epithelial cells led to the same
phenotype of increased cell perimeter and disrupted actin distribution (41,42).
Studies in our laboratory have found that RanBPM also inhibits cell
migration, as downregulation of RanBPM increased cell migration in human
embryonic kidney (HEK) cells (24). These findings are compatible with previous
studies showing that RanBPM interacts with the G protein coupled receptor BLT2
(leukotriene B4 receptor 2) and reduces BLT2-mediated cell migration (43).
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1.2.8. RanBPM in cancer
Evasion of apoptosis, sustained proliferative signal and tissue invasion
mark three of the six primary hallmarks of cancer demonstrated by malignant
cells (3). Given its prominent roles in apoptosis as well as restricting cell growth
and cell migration, it has been suggested that RanBPM might be playing a role in
the prevention of tumour development and oncogenesis. As previously
mentioned, RanBPM has been shown to interact with many pro-apoptotic tumour
suppressors, inhibit proliferative cell pathways and directly induce apoptosis in
response to DNA damage (17-25). It has also been shown to interact with
proteins involved in cell motility and directly inhibit cell migration (24,43).
Interestingly, RanBPM expression has been found to be altered in many human
tumours, including lung, kidney and breast cancer samples (39). In most cases,
expression was lost or greatly reduced, validating its characterization as a
tumour suppressor protein (39).
RanBPM has also been identified in a high-throughput yeast two-hybrid
screen searching for proteins that interact with the C-terminal region of BRCA1
(breast cancer type 1 susceptibility protein), a DNA damage repair tumour
suppressor primarily expressed in breast and ovarian tissues (44). Individuals
with mutations in BRCA1 are undoubtedly considered to be at high risk to
develop breast cancer. Although the functional significance behind the interaction
between RanBPM and BRCA1 was not elucidated, the interaction itself further
suggests roles for RanBPM in DNA damage control and tumour suppressive
activity. Additionally, a breast cancer single nucleotide polymorphism (SNP) was
identified a short distance upstream of the RanBPM gene at nucleotide position
13830502 on chromosome 6 (45). Though the specific impact of this SNP on
RanBPM expression or function has not been determined, this finding implies
that RanBPM may be involved in cancer development and specifically in breast
cancer development.

11

1.2.9. CTLH complex
RanBPM is a known member of the mammalian CTLH complex, along
with Muskelin, Twa1 (two hybrid-associated protein 1 with RanBPM), Rmnd5a
(required for meiotic nuclear division 5 homolog A), MAEA (macrophage
erythroblast attacher) and ARMc8 (armadillo repeat containing 8) (42,46). Each
of these proteins, with the exception of Muskelin, have orthologs in
Saccharomyces cerevisiae which are part of the yeast Gid (glucose induced
degradation deficient) complex (Figure 1.2) (6). Gid1, the ortholog of RanBPM,
acts as a crucial scaffold in this complex and primarily mediates interactions with
other Gid proteins through its LisH and CTLH domains (Figure 1.3) (47). The Gid
complex has been shown to function as an E3 ubiquitin ligase (48). In general,
E3 ubiquitin ligases are key components of the ubiquitin-protease system (UPS)
and act in concert with E1 activating enzymes and E2 ubiquitin conjugating
enzymes to ubiquitinate target proteins and send them for degradation through
the proteasome (49). The Gid complex specifically targets FBPase (fructose-1,6bisphosphatase) for proteasome-mediated degradation when glucose becomes
available and FBPase is no longer needed for yeast to perform gluconeogenesis
(48). Although the Gid complex is a proven E3 ubiquitin ligase in yeast, it is
unknown if the CTLH complex performs a similar function in mammalian cells (6).
However, there has been some evidence of members of the CTLH complex
playing a role in the ubiquitination and degradation of proteins. ARMc8 has been
shown to bind HRS (Hepatocyte growth factor-regulated tyrosine kinase
substrate) and promote its association with ubiquitinated proteins (50). ARMc8
has also been implicated in the proteasome-dependent degradation of α-catenin,
although this was shown to occur independently of ubiquitination (51).
Furthermore, both Rmnd5a and MAEA possess a Really Interesting New Gene
(RING) domain, which is a defining characteristic of many E3 ubiquitin ligases
(6). In fact, evidence suggests that Rmnd5a and its paralog, Rmnd5b, have E3
ubiquitin ligase activity as both have been shown to associate with E2 ubiquitin
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Figure 1.2. Mammalian orthologs of the members of the S. cerevisiae Gid
complex. Proteins found within the Gid complex are represented on the right, along
with their respective mammalian orthologues represented on the left. Conserved
domains are indicated and members of the mammalian CTLH complex are denoted
with an asterisk. Adapted from (6).
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Figure 1.3. Model of the interactions between members of the S. cerevisiae Gid
complex. Gid1, Gid2, Gid4, Gid5, Gid7, Gid8 and Gid9 interact to form an E3
ubiquitin ligase, with the ortholog of RanBPM, Gid1, serving as a central scaffold in
the complex. Orthologs of Gid proteins that are also found in the mammalian CTLH
complex are indicated in italics. Adapted from (47).
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conjugating enzymes and promote the ubiquitination of the prostatic tumour
suppressor NKX3.1 (52).
1.3. c-Raf

1.3.1. Overview of Raf family kinases
The Raf family of serine/threonine kinases have been a hot topic of
research since the discovery of the first raf gene, retroviral oncogene v-raf, in
1983 (53). Mammalian isoforms A-Raf, B-Raf and c-Raf soon generated interest
due to their crucial role as signaling molecules in the ERK pathway, a pathway
known to play an important role in many crucial cellular processes and whose
loss of regulation can be devastating to an organism (54-56). Given that the ERK
pathway is upregulated in approximately one-third of all human cancers (56), it
has become clear that understanding Raf protein function is critical in
understanding the ERK pathway as a whole and its role in cancer development.
The structure of all three mammalian Raf kinases (Figure 1.4) can be
divided into a regulatory N-terminal region and a catalytic C-terminal region. The
N-terminus contains a primary Ras (rat sarcoma) binding site and a cysteine-rich
secondary Ras binding site (54). The C-terminus contains a negative-charge
regulatory region (N-region) and an activation segment, both containing multiple
phosphorylation sites required for Raf activation (54,57), as well as an adenosine
triphosphate (ATP) binding domain. Numerous regulatory phosphorylation sites,
both activating and inhibitory, are also found throughout Raf (54).
A-Raf, B-Raf and c-Raf are all ubiquitously expressed in mammals (58),
although A-Raf and B-Raf levels have been found to be higher in urogenital
organs and neuronal tissues, respectively (59-61). Although all three kinases
have been shown to participate in ERK signaling (54), evidence suggests that the
isoforms also perform additional non-redundant functions. A-Raf knockout mice
tend to die 7–21 days after birth due to neurological and gastrointestinal
deficiencies (62), whereas c-Raf and B-Raf knockout mice die in utero from a
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Figure 1.4. Structure, conserved regions and regulatory phosphorylation sites
of Raf family kinases. (A) General structure of the Raf kinases with conserved
regions indicated. (B) Specific structures of A-Raf, c-Raf and B-Raf with activating
phosphorylation sites (red), inhibitory phosphorylation sites (black), phosphorylation
sites defined as both activating and inhibitory (blue) and autophosphorylation sites
(green) indicated. Adapted from (54).
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different set of complications (63,64). Although both types of mice demonstrate
growth retardation, c-Raf knockout mice exhibit liver defects while B-Raf
knockout mice exhibit vascular and neuronal deficiencies (63,64). Given the
different phenotypes observed in these knockout mice and the apparent lack of
compensation between Raf isoforms, and it is clear that A-Raf, B-Raf and c-Raf
function differently despite their relatively conserved structure.
B-Raf, which is the strongest ERK pathway activator of the Raf family, has
most recently generated interest due to the discovery of common oncogenic
mutations in tumours, such as V600E (54). This mutation mimics phosphorylation
of an activating site within the protein, resulting in a constitutively active form of
B-Raf and persistent ERK pathway signaling (65). Prior to this discovery,
however, c-Raf, the 70kDa isoform also known as Raf-1, was the primary isoform
under investigation and thus still remains one of the best characterized Raf
kinases (54).
1.3.2. ERK signaling pathway
As previously mentioned, Raf is an important component of the ERK
signaling pathway (Figure 1.5). Overall, the ERK pathway has been reported to
regulate numerous cellular processes, including cell survival, differentiation,
proliferation, motility, transcription and metabolism (54,55). To summarize
signaling within the pathway, cell membrane embedded receptor tyrosine kinases
(RTKs) are first activated by extracellular ligands and autophosphorylation occurs
on the intracellular domains of the receptors (54). The guanine nucleotide
exchange factor SOS (son of sevenless) and the adaptor protein Grb2 (adaptor
protein growth factor receptor-bound protein 2) are subsequently recruited to the
phosphorylated intracellular domains of the receptor (54). SOS activates the cell
membrane-linked protein Ras by exchanging its guanosine diphosphate (GDP)
for guanosine triphosphate (GTP) (54). Activated Ras initiates a cascade of
phosphorylation events where Ras activates Raf, which promotes the activation
of MEK1/2 (mitogen-activated protein kinase kinase 1/2), which finally activates
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Figure 1.5. Summary of ERK pathway signaling. Extracellular signals promote
RTK activation and autophosphorylation. Intracellular Grb2 and SOS are recruited to
the phosphorylated receptor, and subsequently promote the exchange of GDP for
GTP on membrane-bound Ras. Activated Ras initiates a cascade of activating
phosphorylation events involving Raf, MEK and ERK, respectively. Activated ERK
has countless substrates in both the cytoplasm and nucleus, including the
transcription factor CREB which, when activated, induces transcription of antiapoptotic factors Bcl-2 and Bcl-XL.
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ERK1/2 (54). Phosphorylated active ERK1/2 has over 150 reported targets in the
cell, both nuclear and cytoplasmic (54,66).
For example, one of the outcomes of ERK1/2 phosphorylation is the
activation of the transcription factor CREB (cAMP response element-binding
protein) and the subsequent increase in transcription of certain anti-apoptotic
factors, such as Bcl-2 and Bcl-XL (67). Other well-known targets of ERK1/2
include the transcription factors Elk1 (ETS domain-containing protein) and c-Fos
(cellular FBJ murine osteosarcoma viral oncogene homolog), the kinases DAPK
(death associated protein kinase) and MSK1/2 (mitogen- and stress-activated
protein kinases 1/2) and the cytoskeletal element paxillin (66).
Furthermore, a number of scaffolding proteins have been shown to
interact with components of the ERK pathway to facilitate signaling. The bestcharacterized scaffolds include KSR1 (kinase suppressor of Ras 1) and the
IQGAP (IQ motif containing GTPase-activating protein) family of proteins,
although there are many other scaffolds that have been reported to localize ERK
pathway signaling to various compartments within the cell (55).
1.3.3. MEK1/2-independent signaling by c-Raf
Although it has been argued that MEK1/2 is the only Raf substrate
(54,58), there is also emerging evidence that Raf is able to regulate a number of
signaling molecules independent of the ERK pathway. Given that B-Raf is the
primary Raf isoform involved in MEK1/2 activation, it has been suggested that cRaf and A-Raf have evolved other functions (54,68). For example, adenylyl
cyclases (ACs) 2, 5 and 6 have been reported to be phosphorylated and
activated by c-Raf (69,70). Given that PKA deactivates c-Raf, and PKA is
indirectly activated by ACs, activation of ACs by c-Raf would appear to contribute
to negative feedback regulation of c-Raf. Rb (retinoblastoma tumour suppressor
protein) has also been shown to be a phosphorylation target of c-Raf, an event
which leads to the inactivation of Rb and consequential cell cycle progression
(71).
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Although c-Raf is a well-characterized kinase, it also affects signaling of
some proteins in a kinase-independent manner. For instance, the pro-apoptotic
proteins ASK1 (apoptosis signal-regulating kinase 1) and MST2 (mammalian
Ste20-like kinase 2) are negatively regulated through direct binding with c-Raf
(72,73). Rok-α (Rho-binding kinase α) is also inhibited solely by c-Raf binding, a
phenomenon that regulates cell motility and protects against apoptosis (74,75).
1.3.4. c-Raf activation and deactivation
Due to the aforementioned implications of deregulation of the ERK
pathway, c-Raf activity is tightly controlled. Regulation of c-Raf activity is a
complex process that involves a number of proteins and many phosphorylation
and dephosphorylation events. In an inactive state, the N-terminus of c-Raf is
folded over and stabilized by a 14–3–3 protein dimer in a conformation that
masks the C-terminus (Figure 1.6A) (76). 14–3–3 specifically interacts with c-Raf
on two phosphorylated residues, S259 and S621 (77). To activate c-Raf, S259 is
dephosphorylated by phosphatases PP2A (protein phosphatase 2A) and PP1
(protein phosphatase 1) and 14–3–3 is released from this binding site (Figure
1.6B) (78). Conformational changes occur which displace the N-terminal
regulatory domain of c-Raf from the C-terminal catalytic domain, thus revealing
the primary and secondary Ras binding sites previously sequestered within c-Raf
(Figure 1.6C) (79). Ras is allowed to bind c-Raf and kinases are recruited to
phosphorylate activating sites on c-Raf (Figure 1.6D). These sites include several
sites in the activation segment as well as S338, S339, Y340 and Y341 in the Nregion (80,81). Phosphorylation of amino acids 338–341 is essential for full c-Raf
activation and also for interaction with its substrate MEK1/2 (82). PAK1 (p21activated kinase 1), JAK2 (Janus kinase 2), Src (sarcoma) and CK2 (casein
kinase 2) have each been reported to phosphorylate a subset of these residues
(76,83,84), although there are likely other kinases involved that have yet to be
identified (54). A number of other phosphorylation sites have been reported to
enhance c-Raf activity (54) and c-Raf heterodimerization with B-Raf has also
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Figure 1.6. Summary of the activation cycle of c-Raf. (A) The N-terminal
regulatory region of c-Raf (light blue) sequesters the C-terminal catalytic region (dark
blue) in a closed inactive conformation stabilized by 14–3–3 (orange). The
interaction between c-Raf and 14–3–3 is stabilized by the phosphorylated residues
(black) S259 and S621 on c-Raf. (B) S259 is dephosphorylated and 14–3–3 is
released from the c-Raf N-terminus, creating a semiclosed inactive conformation.
(C) c-Raf adapts an open inactive conformation, where the N-terminus unmasks the
C-terminus and binds membrane-bound Ras (green). (D) The C-terminus of c-Raf is
phosphorylated on a number of residues, leading to an open active form of the
protein. Adapted from (79).
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been proposed to increase kinase activity compared to monomeric or
homodimeric versions of either protein (85).
During c-Raf deactivation, the phosphorylated N-region serves as a
binding site for RKIP (Raf kinase inhibitor protein) (86), which dissociates
MEK1/2 from c-Raf (87). PP5 (protein phosphatase 5) binds c-Raf and promotes
the dephosphorylation of S338 (88) while PP2A dephosphorylates other
activating sites (89). PKA (protein kinase A) has also been reported to contribute
to c-Raf deactivation, phosphorylating S43 and S233, which interfere with Ras
binding, as well as S259, which interferes with Ras binding and contributes to
14–3–3 binding (90,91). Altogether, these events return c-Raf to its inactive state,
stabilized in a closed conformation by 14–3–3.
1.3.5. Regulation of c-Raf stability
In addition to the abundance of phosphorylation and dephosphorylation
events that regulate c-Raf activity, there are also some systems known to
regulate c-Raf stability and overall c-Raf levels within the cell. One well-known
regulator of c-Raf stability is the chaperone protein Hsp90 (heat shock protein
90). Hsp90 is a highly conserved molecular chaperone that mediates the folding
of newly synthesized or misfolded client proteins, assembles and disassembles
molecular complexes and prevents protein aggregation (92). Hsp90 does not
perform these tasks alone, however, as it has been shown to form complexes
with over 20 co-chaperones (92).
Although Hsp90 generally functions to help rescue client proteins, it has
also been shown to form a complex with Hsp70 (heat shock protein 70), another
molecular chaperone, and CHIP (C-terminus of Hsp70-interacting protein), an E3
ubiquitin ligase, to target terminally misfolded proteins for ubiquitination and
degradation by the proteasome (92,93). Hsp90 has been shown to bind and
stabilize the tertiary structure of c-Raf, allowing it to localize to the membrane,
interact with Ras and properly engage in ERK pathway signaling (94-96).
Disruption of binding between the two proteins results in proteasomal
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degradation of c-Raf (97). There has been evidence that CHIP is able to
ubiquitinate c-Raf, suggesting that CHIP is an E3 ubiquitin ligase responsible for
proteasomal degradation of the kinase (98,99). XIAP (X-linked inhibitor of
apoptosis), a member of the IAP (inhibitor of apoptosis) family of proteins, has
been shown to be a modulator of CHIP-mediated c-Raf degradation. Although
XIAP itself is an E3 ubiquitin ligase, evidence suggests that XIAP interferes with
c-Raf stability and promotes recruitment of CHIP to Hsp90 and c-Raf,
independently of its ubiquitin ligase activity (99).
There has also been evidence of c-Raf degradation by mechanisms that
do not rely on CHIP. It has been reported that autophosphorylation of S621 is
necessary for c-Raf stabilization, as kinase-dead mutants were ubiquitinated and
targeted to the proteasome (100). This occurred even when CHIP levels were
knocked-down by siRNA, suggesting that other E3 ubiquitin ligases may also
play a role in c-Raf downregulation (100). c-Raf has also been shown to be
ubiquitinated and degraded by the proteasome in response to disruption of cell
adhesion and treatment with the oxidative glucose metabolite methylglyoxal,
however the mechanisms by which these events occurred were not determined
(101,102).
Studies conducted in our laboratory have shown that c-Raf is
downregulated by RanBPM, as shRNA-mediated RanBPM knock-down led to
increased c-Raf protein levels and re-expression of RanBPM reversed this effect
(24). Downregulation was observed for both endogenous c-Raf and transfected
constitutively active c-Raf, but the effect was more prominent on the latter (24).
RanBPM shRNA knock-down also led to increased levels of Bcl-2, Bcl-XL,
phosphorylated ERK1/2 and phosphorylated MEK1/2 and re-expression of
RanBPM reversed these effects in multiple cell lines (24). This suggests that,
through its effect on c-Raf, RanBPM is an inhibitor of the ERK pathway. These
studies further demonstrated, via immunoprecipitation and pull-down assays, that
RanBPM is found in a complex with endogenous c-Raf and can also form a
complex with constitutively active c-Raf, consisting only of the catalytic region of
the protein (24). RanBPM was also shown to disrupt c-Raf association with
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Hsp90, providing insight on a potential mechanism by which c-Raf could be destabilized by RanBPM (24). However, further studies exploring this concept have
yet to be conducted and other mechanisms could also contribute to c-Raf
downregulation by RanBPM.
1.4. Hypothesis and objectives
Work in our laboratory has shown that RanBPM and c-Raf are found
together in a complex and that RanBPM downregulates c-Raf at the protein level
(24). However, how the two proteins interact and the mechanism by which
RanBPM downregulates c-Raf remains unknown. Therefore, it is hypothesized
that specific domains of RanBPM are required for direct interaction with c-Raf
and regulation of c-Raf stability by a mechanism that could involve the CTLH
complex. The work presented in this thesis aims to specifically address the
following objectives:
(1) Determine which domain(s) of RanBPM are required for regulation of cRaf stability.
(2) Identify which domain(s) of RanBPM are required for interaction with cRaf.
(3) Investigate the possibility of CTLH complex involvement in c-Raf
downregulation.
It has become evident that investigating the key mechanisms that tightly
regulate the activity and stability of the components of the ERK pathway, namely
c-Raf, is critical in understanding the devastating consequences associated with
the loss of regulation of this pathway and can contribute to the development of
new therapies to combat cancer. Furthermore, in light of the recent identification
of RanBPM as an activator of apoptosis, a better understanding of its effect on cRaf will help elucidate its role as a critical tumour suppressor. Overall, the work
presented in this thesis clarifies the relationship between two important proteins
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that play critical roles in cell growth, differentiation, apoptosis and cancer
development.
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Chapter 2 – Materials and Methods
2.1. Chemicals and reagents
All enzymes and buffers used for cloning were obtained from either New
England Biolabs Inc. (Ipswich, MA, USA) or Fermentas Thermo Fisher Scientific
Inc. (Waltham, MA, USA) and were used according to the manufacturer’s
protocol. Hydrochloric acid (HCl) was also acquired from Thermo Fisher
Scientific Inc. Fetal bovine serum (FBS), trypsin, L-glutamine, sodium pyruvate,
paraformaldehyde (PFA), sodium chloride (NaCl), ethylenediaminetetraacetic
acid (EDTA), hydroxyethyl piperazineethanesulfonic acid (HEPES), sodium
dodecyl sulfate (SDS), Tris-hydroxymethyl amino methane (Tris) and potassium
chloride (KCl) were purchased from Wisent Inc. (St. Bruno, QC, Canada), while
Dulbecco’s modified eagle medium (DMEM) and phosphate buffered saline
(PBS) were purchased from both Gibco by Life Technologies Inc. (Burlington,
ON, Canada) and Wisent Inc. G418 sulphate, Triton X-100, Nonidet P-40
(NP40), aprotinin, leupeptin, pepstatin, dithiothreitol (DTT), sodium fluoride
(NaF), sodium orthovanadate (NaVO4), pheylmethylsulfonyl fluoride (PMSF) and
isopropyl β-D-1-thiogalactopyranoside (IPTG) were purchased from BioShop Inc.
(Burlington, ON, Canada) while glycerol was acquired from Caledon Laboratory
Chemicals Ltd. (Georgetown, ON, Canada).
2.2. Antibodies
Primary antibodies used were RanBPM (K-12, sc-46253 and F-1, sc271727, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), c-Raf (E-10, sc7267 and C-12, sc-133, Santa Cruz Biotechnology Inc.), β-actin (I-19, sc-1616-R,
Santa Cruz Biotechnology Inc.), human influenza hemagglutinin (HA) (HA-7,
H3663, Sigma-Aldrich Inc., Oakville, ON, Canada), glutathione-S-transferase
(GST) (B-14, sc-138, Santa Cruz Biotechnology Inc.), Hsp90 α/β (H-114, sc7947, Santa Cruz Biotechnology Inc.) and MAEA (ab65239, Abcam Inc.,
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Cambridge, MA, USA). For each application, primary antibodies were used in the
concentrations indicated in Table 2.1.
Secondary antibodies used for Western blot analyses were Peroxidaseconjugated AffiniPure Goat anti-Mouse IgG (H+L) (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA) and Blotting Grade Goat anti-Rabbit
IgG (H+L) (Human IgG Adsorbed) Horseradish Peroxidase Conjugate (Bio-Rad
Laboratories Inc., Mississauga, ON, Canada). Both were used at a concentration
of 1:5000.
2.3. Plasmid constructs
pCMV-HA-RanBPM was a gift from Dr. Mark Nelson (University of
Arizona, Tucson, AZ, USA) and was rendered resistant to shRNA degradation
via the introduction of two silent point mutations as described in (18). RanBPM
deletion mutants pCMV-HA-RanBPM-ΔN2, pCMV-HA-RanBPM-ΔC4, pCMV-HARanBPM-ΔC1, pCMV-HA-RanBPM-Δ212, and pCMV-HA-RanBPM-Δ360 were
generated as described in (18,103). pEBG-GST-ΔN-c-Raf was a gift from Dr.
Zhijun Luo (Boston University, Boston, MA, USA).
pET28a-ΔN-c-Raf was generated by isolating a fragment encoding ΔN cRaf from pEBG-GST-ΔN-c-Raf using BamHI and NotI, and ligating into the
bacterial expression vector pET28a (EMD Millipore, Billerica, MA, USA) using T4
DNA

ligase.

pGEX4T1-GST-WT-RanBPM,

pGEX4T1-GST-N2-domain

and

pGEX4T1-GST-C1-domain were generated by polymerase chain reaction (PCR)
amplifying full-length WT RanBPM, RanBPM amino acids 1–102 or RanBPM
amino acids 649–729, respectively, from pCMV-HA-RanBPM. PCR was
performed using KOD Hot Start Polymerase PCR kit (EMD Millipore) according
to the manufacturer’s protocol. Primers used for PCR are outlined in Table 2.2.
PCR products were subsequently digested with BamHI and SalI-HF and were
each ligated into the bacterial expression vector pGEX-4T-1 (GE Healthcare Life
Sciences, Little Chalfont, Buckinghamshire, UK) using T4 DNA ligase.
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Table 2.1. Concentrations of primary antibodies used for Western blot and in
situ proximity ligation assay.

Species

Western blot
concentration

In situ proximity ligation
assay concentration

goat

N/A

1:400

RanBPM (F-1)

mouse

N/A

1:50

c-Raf (E-10)

mouse

1:500

1:50

c-Raf (C-12)

rabbit

1:500

N/A

β-actin (I-19)

rabbit

1:2000

N/A

HA (HA-7)

mouse

1:1000

N/A

GST (B-14)

mouse

1:500

N/A

Hsp90 α/β (H-114)

rabbit

N/A

1:100

MAEA (ab65239)

rabbit

N/A

1:200

Antibody
RanBPM (K-12)
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Table 2.2. PCR primer sequences and descriptions.

Primer

RBPMfwdBamHI

Sequence (5’ to 3’)

Description

GCTAGGATCCATGTCCGGGCAGCCGCCG

forward PCR
primer to amplify
WT RanBPM
and N2 domain

Tm

70.1°C

RBPMrevSalI

65.6°C

CGCGGTACGTCGACTAATGTAGGTAGTCTTCC

reverse PCR
primer to amplify
WT RanBPM
and C1 domain

N2domrevSalI

68.8°C

GTATGTCGACTACCCGCTGGCGGGGGC

reverse PCR
primer to amplify
N2 domain

C1domfwdBamHI

64.3°C

CGATGGATCCAAGGATGCATTCAGTCTACTAGC

forward PCR
primer to amplify
C1 domain

29

2.4. Stable shRNA cell lines and cell culture
HeLa cells were obtained from the American Type Culture Collection
(Manassus, VA, USA). HeLa cell lines stably expressing either RanBPM shRNA
(clone 2-7) or control shRNA were generated as described in (18). HeLa 2-7 cells
and HeLa control cells were cultured in DMEM supplemented with 8% FBS, 1%
sodium pyruvate, 1% L-glutamine, 4.5g/L glucose and 0.35g/L G418 sulphate at
37°C in 5% CO2. Cells were washed with PBS and detached with trypsin upon
passaging.
2.5. In situ proximity ligation assay
To prepare for the Duolink II in situ proximity ligation assay (PLA) (SigmaAldrich Inc.), cover slips were pre-treated by outlining with the hydrophobic
ImmEdge pen (Vector Laboratories Inc., Burlingame, CA, USA). HeLa cells were
seeded on these cover slips at approximately 50,000 cells per cover slip, fixed
with 4% PFA for 13 minutes at 4°C, permeabilized with 0.5% Triton X-100 for 10
minutes at room temperature, and blocked for 1 hour with 5% FBS in PBS at
room temperature. Cover slips were incubated in the appropriate primary
antibodies at the concentrations indicated in Table 2.1 overnight at 4°C.
Manufacturer’s instructions were followed for the in situ PLA. Cover slips were
mounted onto glass slides with Prolong Gold antifade reagent with DAPI
(Molecular Probes by Life Technologies, Burlington, ON, Canada) and were
subsequently analyzed at 358nm (nucleus) and either 555nm or 647nm
(fluorescent oligonucleotide probe) with an Olympus BX51 microscope (Olympus
America Inc., Center Valley, PA, USA) using a 40x objective. Images were
captured using Image-Pro Plus v4.5 software (Media Cybernetics Inc., Bethesda,
MD, USA).
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2.6. Transfection assays
ExGen 500 in vitro Transfection Reagent (Fermentas Thermo Fisher
Scientific Inc.), TurboFect Transfection Reagent (Thermo Fisher Scientific Inc.)
and JetPRIME Transfection Reagent (PolyPlus Transfection, Illkirch, France)
have all been used according to the manufacturer’s instructions for transfection
of HeLa cells. For each pCMV-HA RanBPM deletion mutant, the amount of
construct transfected was adjusted to account for variations in stability between
the expressed proteins. In all cases, the amount of DNA used was brought up to
the

manufacturer’s

recommendations

with

the

vector

pBS-SK

(Agilent

Technologies, Santa Clara, CA, USA). Transfected cells were incubated 24–48
hours at 37°C in 5% carbon dioxide (CO2).
2.7. Preparation of mammalian cell extracts
HeLa cells were scraped in cold PBS, centrifuged at 8000rpm for 3
minutes, lysed for 40 minutes on ice in whole cell extract (WCE) buffer (150mM
NaCl, 1mM EDTA, 50mM HEPES pH 7.4 and 10% glycerol) and supplemented
with 0.5% NP40, 0.5% Triton X-100, 10μg/mL aprotinin, 2μg/mL leupeptin,
2.5μg/mL pepstatin, 1mM DTT, 2mM NaF, 2mM NaVO4, and 0.1mM PMSF. The
lysate was centrifuged at 13,000rpm for 20 minutes at 4°C and the resulting
supernatant was collected.
2.8. Bacterial protein expression and preparation of Escherichia coli
extracts
For each bacterial expression construct, plasmids were transformed into
E. coli strain BL21DE3. Single transformants were selected and grown in Luria
Bertani (LB) medium overnight at 37°C. This culture was diluted 1:150 into fresh
LB medium and grown to an optical density at 600nm (OD600) between 0.4–0.5.
Protein expression was induced with 0.1mM IPTG and the culture was incubated
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overnight at 16°C. Bacteria was centrifuged at 4000rpm for 20 minutes at 4°C
and subsequently resuspended in lysis buffer (25mM HEPES pH 7.4, 10mM KCl,
2mM EDTA and 20% glycerol) supplemented with 0.1% NP40, 10μg/mL
aprotinin, 2μg/mL leupeptin, 2.5μg/mL pepstatin, 1mM DTT, 2mM NaF, 2mM
NaVO4, and 0.1mM PMSF. The cell suspension was sonicated three times for 10
seconds on ice using the Sonic Dismembrator Model 100 (Thermo Fisher
Scientific Inc.), centrifuged at 13,000rpm for 10 minutes at 4°C and the resulting
supernatant was collected.
2.9. Western blot analyses
Samples were resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on either 8% or 10% acrylamide gels and
subsequently transferred for either for 1 hour at 100V or overnight at 25V onto a
polyvinylidene fluoride (PVDF) membrane. Blots were blocked in 5% non-fat dry
milk for at least 1 hour at room temperature, then incubated in primary antibody
diluted in 5% non-fat dry milk as indicated in Table 2.1 overnight at 4°C or for 1
hour at room temperature. Blots were incubated in secondary antibody diluted in
5% non-fat dry milk for 1 hour at room temperature and developed using either
Western Lightning Enhanced Chemiluminescence (ECL) Substrate (Perkin Elmer
Inc., Waltham, MA, USA) or Clarity Western ECL Substrate (Bio-Rad
Laboratories Inc.). Images were captured using either Kodak X-OMAR LS film
(Carestream Health Inc., Rochester, NY, USA) or the ChemiDoc MP (Bio-Rad
Laboratories Inc.) and Image Lab software (Bio-Rad Laboratories Inc.).
2.10. GST pull-down assays

2.10.1. Using HeLa cell extracts
Extracts were quantified and 1800μg total protein was aliquoted for each
pull-down sample. Extracts were brought up to 1mL with WCE buffer to a final
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concentration of 0.4% NP40, 0.4% Triton X-100, 20μg/mL aprotinin, 4μg/mL
leupeptin, 5μg/mL pepstatin, 2mM DTT, 4mM NaF, 4mM NaVO4, and 0.2mM
PMSF. Glutathione-Agarose beads (Sigma-Aldrich Inc.) suspended in PBS were
added to each sample to a final concentration of 5μL beads/100μg total protein
and pull-down samples were incubated overnight at 4°C. Beads were
subsequently washed three times in WCE buffer supplemented with 0.4% NP40,
0.4% Triton X-100, 1mM DTT and 0.1mM PMSF. Beads were resuspended in
SDS loading dye (0.105g/mL SDS, 0.093g/mL DTT, 0.35M Tris HCl pH 6.8 and
30% glycerol), boiled for 5 minutes and centrifuged at 10,000rpm for 10 seconds.
The resulting supernatant was collected and analyzed by Western blot.
2.10.2. Using E. coli extracts
Extracts

were

quantified

and,

for

each

GST-tagged

construct,

approximately 400μg total protein was used for each pull-down sample. Samples
were brought up to 200μL with lysis buffer and subsequently brought up to 600μL
with binding buffer (15mM HEPES pH 7.4, 6mM KCl, 1.2mM EDTA and 12%
glycerol) to a final concentration of 0.6% NP40, 0.6% Triton X-100, 10μg/mL
aprotinin, 2μg/mL leupeptin, 2.5μg/mL pepstatin, 1mM DTT, 2mM NaF, 2mM
NaVO4, and 0.1mM PMSF. Samples were incubated for 2 hours at 4°C with 30μL
Glutathione-Agarose beads. Beads were washed three times with binding buffer
supplemented with 0.6% NP40, 0.6% Triton X-100, 1mM DTT and 0.1mM PMSF.
Each sample was then incubated with 200μg ΔN c-Raf extract and brought up to
800μL with binding buffer to a final concentration of 0.6% NP40, 0.6% Triton X100, 10μg/mL aprotinin, 2μg/mL leupeptin, 2.5μg/mL pepstatin, 1mM DTT, 2mM
NaF, 2mM NaVO4, and 0.1mM PMSF. Samples were again incubated for 2 hours
at 4°C and beads were washed with binding buffer supplemented with 0.6%
NP40, 0.6% Triton X-100, 1mM DTT and 0.1mM PMSF. Beads were
resuspended in SDS loading dye, boiled for 5 minutes and centrifuged at
10,000rpm for 10 seconds. The resulting supernatant was collected and
analyzed by Western blot.
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2.11. Statistical analyses
Using Microsoft Office Excel 2007 (Microsoft Corporation, Redmond, WA,
USA), one-way analysis of variance (ANOVA) was performed to compare
multiple groups and two-sample t-test assuming unequal variance was performed
to compare pairs of groups. Graphed data are presented as mean ± standard
error of the mean (SEM) and are determined to be significant when p < 0.05. The
number of independent replicates for each experiment is denoted as N.
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Chapter 3 – Results
3.1. Endogenous RanBPM and c-Raf are found in a complex
Previous co-immunoprecipitation and pull-down experiments in our
laboratory have demonstrated that RanBPM and c-Raf exist together in a
complex (24). Since this was shown using ectopically expressed protein
constructs, we sought to confirm that the complex occurs with the endogenous
proteins in cells. The in situ PLA, an assay that allows visualization of proteinprotein interactions in cells using fluorescence microscopy (Figure 3.1) (104),
was thus used to visualize the interaction between endogenous RanBPM and cRaf in HeLa cells.
To summarize the PLA, fixed and permeabilized cells are incubated with
primary antibodies against two proteins of interest. Two types of specialized
secondary antibodies fused to short DNA strands, called PLA probes, are then
incubated with the cells to bind their respective primary antibodies. When two
different PLA probes come within 40nm of each other, the DNA strands are
ligated together and amplified by a polymerase in a process termed rolling-circle
amplification. The amplified DNA product is then hybridized with a fluorescently
labeled complementary oligonucleotide probe, which is then visualized by
fluorescence microscopy. Each fluorescent dot seen represents a protein-protein
interaction between the two proteins of interest.
Stable HeLa cell lines expressing either a control or RanBPM shRNA
(clone 2-7), which were previously generated in our laboratory (18), were used in
this experiment. To ensure the PLA probes did not confer any background signal,
a control was performed where HeLa control cells were incubated without
primary antibodies. To gauge the specificity of the RanBPM primary antibody,
another control was included where HeLa 2-7 cells were incubated with primary
antibodies against RanBPM and c-Raf. As expected, fluorescent dots
representing interactions were not observed in either negative control (Figures
3.2A and 3.2B).
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Figure 3.1. Summary of the in situ PLA. Primary antibodies against two proteins of
interest are incubated with fixed and permeabilized cells. Secondary antibodies
attached to short DNA strands, called PLA probes, are incubated with the cells and
allowed to bind the primary antibodies. When two PLA probes come within 40nm of
each other, ligation with special oligonucleotides anneal the two PLA probe DNA
strands and allow them to form a circle. This circle of DNA is amplified using a
polymerase, and this amplified product is hybridized with a fluorescently labeled
oligonucleotide probe. Each protein-protein interaction is represented as a
fluorescent dot which can be visualized by fluorescence microscopy.
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Figure 3.2. Endogenous RanBPM and c-Raf are found in a complex. An in situ
PLA was performed in (A) HeLa control cells, without the addition of primary
antibodies (negative control); (B) HeLa 2-7 cells, using primary antibodies against cRaf and RanBPM (negative control); (C) HeLa control cells, using primary antibodies
against Hsp90 and RanBPM (positive control); (D) HeLa control cells, primary
antibodies against using c-Raf and RanBPM. DAPI staining was used to visualize
the nuclei at 358nm, while the PLA dots representing protein-protein interactions
were visualized at 555nm.
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Given that c-Raf is known to interact with Hsp90 (96), a positive control
was included where HeLa control cells were incubated with antibodies against cRaf and Hsp90. This did expectedly produce fluorescent dots representing
interactions (Figure 3.2C). In HeLa control cells in which antibodies against c-Raf
and RanBPM were included for the assay, fluorescent dots were observed,
confirming that the two endogenously expressed proteins are found together in a
complex (Figure 3.2D).
3.2. The N-terminus, CRA and LisH/CTLH domains of RanBPM are required
for c-Raf downregulation
Previous experiments in our laboratory have also demonstrated that
RanBPM downregulates c-Raf at the protein level (24). Given that RanBPM
contains a number of conserved domains, we strove to determine which regions
of RanBPM were necessary for downregulation of c-Raf. In order to achieve this,
we used a series of RanBPM deletion mutant constructs (Figure 3.3), which have
been cloned into the mammalian expression vector pCMV-HA (18,103), to test
their effects on levels of ΔN c-Raf. ΔN c-Raf, a constitutively active construct of
c-Raf containing only amino acids 325-648 (82), was used instead of full-length
c-Raf because RanBPM has been shown to have a greater effect on activated cRaf (24). By using this construct, we allowed ourselves to observe the most
pronounced effect of each RanBPM deletion mutant on c-Raf levels, enabling us
to better discern which mutants have lost their ability to downregulate c-Raf.
Furthermore, since RanBPM is able to dimerize (13), we opted to perform our
experiments in HeLa 2-7 cells to avoid dimerization between mutant RanBPM
and endogenous WT RanBPM monomers. Thus, in our system, HeLa 2-7 cells
were transfected with pEBG-GST-ΔN-c-Raf as well as either pCMV-HA vector,
pCMV-HA-RanBPM or a pCMV-HA RanBPM deletion mutant. Cell extracts were
prepared and the effect of each RanBPM mutant on levels of c-Raf was analyzed
by Western blot.
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Figure 3.3. Full-length RanBPM and deletion mutants chosen for analysis. WT,
ΔN2, ΔC4, ΔC1, Δ212, and Δ360 RanBPM constructs were cloned into the
mammalian expression vector pCMV-HA.
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As previously reported (24), WT RanBPM was able to significantly
downregulate ΔN c-Raf compared to the levels of ΔN c-Raf seen in the pCMVHA control, resulting in a 2.08 ± 0.44 fold decrease of ΔN c-Raf expression
(Figures 3.4A-D). Furthermore, Δ212 RanBPM was also able to downregulate
ΔN c-Raf compared to the levels of ΔN c-Raf seen in the pCMV-HA control,
demonstrating a significant 1.58 ± 0.45 fold decrease of ΔN c-Raf expression
(Figures 3.4A and 3.4C). Although it would appear from the representative image
that Δ212 RanBPM was able to downregulate ΔN c-Raf better than WT RanBPM,
Δ212 RanBPM actually demonstrated better expression in this experiment and
therefore more protein was likely available to exert its effect on ΔN c-Raf (Figure
3.4A). Overall, the effects that Δ212 RanBPM and WT RanBPM demonstrated on
ΔN c-Raf were not significantly different from one another (Figure 3.4C),
indicating that the SPRY domain is not required for c-Raf destabilization.
ΔN2 RanBPM, however, was unable to effectively downregulate ΔN c-Raf
and resulted in a significant 3.14 ± 0.60 fold increase when compared to the
levels of ΔN c-Raf seen in response to WT RanBPM (Figures 3.4A and 3.4C).
ΔN c-Raf expression in response to this mutant was not significantly different
than that observed in the pCMV-HA control (Figure 3.4A and 3.4C). The
expression of ΔN2 RanBPM is consistently much lower than that of the other
RanBPM deletion mutants, despite identical transfection conditions, and thus our
laboratory has hypothesized that the protein is very unstable (16,18). Despite this
phenomenon, levels of ΔN2 RanBPM near those of WT RanBPM were achieved
in this experiment (Figure 3.4A) and therefore it is reasonable to conclude that
ΔN2 RanBPM has lost its ability to downregulate ΔN c-Raf. This implies that the
N-terminus of RanBPM is required for its effect on c-Raf.
Δ360 and ΔC4 RanBPM also did not effectively downregulate ΔN c-Raf,
as ΔN c-Raf expression levels were significantly higher than those seen in
response to WT RanBPM, demonstrating 4.68 ± 1.15 and 3.34 ± 0.71 fold
increases respectively, and were not significantly different than those seen in the
pCMV-HA control (Figures 3.4A and 3.4C). This occurred despite the fact that
expression of these mutants was remarkably higher than that of WT RanBPM.
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Figure 3.4. Δ360, ΔN2, ΔC4 and ΔC1 RanBPM deletion mutants do not
effectively downregulate ΔN c-Raf compared to WT RanBPM. HeLa 2-7 cells
were transfected with pEBG-GST-ΔN-c-Raf and either pCMV-HA, pCMV-HARanBPM or pCMV-HA RanBPM deletion mutant constructs. Extracts were analyzed
by Western blot. (A,B) Representative images are shown. (C,D) Multiple
experiments were quantified by normalizing ΔN c-Raf levels to the loading control, βactin, and statistical analyses were performed (N 4–25, SEM shown).
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These results suggest that the LisH/CTLH domains and the C-terminus of
RanBPM play a role in c-Raf downregulation. However, considering that the ΔC4
deletion removes a very large portion of RanBPM, we decided to repeat the
experiment using a construct harboring only a deletion of the CRA domain,
namely the ΔC1 RanBPM construct. ΔC1 RanBPM behaved nearly identically to
ΔC4 RanBPM in its inability to downregulate ΔN c-Raf and resulted in a 3.76 ±
1.15 fold increase when compared to the levels of ΔN c-Raf seen in response to
WT RanBPM, (Figures 3.4B and 3.4D). This implies that within the C-terminus of
RanBPM, it is specifically the CRA domain that is needed for c-Raf
downregulation.
Altogether, these results demonstrate that the N-terminus, LisH/CTLH and
CRA domains are required for c-Raf destabilization, since loss of any of these
regions render RanBPM unable to effectively downregulate c-Raf.
3.3. The CRA domain of RanBPM is required for interaction with c-Raf
To continue to characterize the interaction between RanBPM and c-Raf,
we aimed to determine the domain or domains of RanBPM required for the
interaction. To accomplish this, we used the same system outlined in section 3.2
and used the extracts to perform GST pull-down assays to test which RanBPM
deletion mutants have retained their ability to interact with ΔN c-Raf.
Specifically, HeLa 2-7 cells were transfected with either pEBG-GST and
pCMV-HA-RanBPM, or pEBG-GST-ΔN-c-Raf and either pCMV-HA-RanBPM or a
pCMV-HA RanBPM deletion mutant. Due to its poor stability, ΔN2 RanBPM was
not among the mutants tested as we were unable to obtain sufficient levels of the
protein to detect it in this type of assay. Cell extracts were prepared and
Glutathione-Agarose beads were incubated with the resulting extracts to pulldown GST or GST-ΔN-c-Raf, as well as any RanBPM deletion mutant associated
with it. Pull-down samples were analyzed by Western blot.
As anticipated based on previous studies (24), GST-ΔN-c-Raf was able to
successfully pull-down WT RanBPM in the positive control, while, as expected for
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the negative control, GST alone only pulled-down background levels of WT
RanBPM (Figures 3.5A-C). Δ212 RanBPM and Δ360 RanBPM both retained
their abilities to interact with ΔN c-Raf, as levels of pulled-down RanBPM were
not significantly different than those of the positive control but were significantly
higher than those of the negative control (Figures 3.5A-C). This indicates that the
SPRY and LisH/CTLH domains are not required for the interaction between
RanBPM and c-Raf, since deletion of these regions does not nullify the
interaction.
However, ΔC1 RanBPM was not able to effectively interact with ΔN c-Raf,
as the amount of ΔC1 RanBPM associating with ΔN c-Raf resulted in a
significant 2.12 ± 0.19 fold decrease compared to the amount of WT RanBPM
associating with ΔN c-Raf, but was not significantly different than the level of
interaction seen in the negative control (Figures 3.5A and 3.5C). Altogether, this
data suggests that the CRA domain is the only domain tested that appears to be
required for the interaction between RanBPM and c-Raf, since deletion of this
region abolishes the interaction.
3.4. RanBPM interacts directly with c-Raf through the CRA domain
Further tests were needed to confirm the interaction between the CRA
domain of RanBPM and c-Raf. Also, the nature of the interaction, whether it be
direct or mediated by another factor, remained to be determined. Therefore, to
address this matter, we aimed to repeat pull-down experiments using bacterial
extracts. By expressing our mammalian RanBPM and c-Raf constructs in E. coli,
we ensured that no other mammalian proteins were present to mediate the
interaction between our two proteins of interest. Thus, if the interaction was to
persist in this system, it was assumed to be direct.
We opted to clone individual domains of RanBPM, as well as WT
RanBPM, downstream of GST into the bacterial expression vector pGEX-4T-1
(Figure 3.6). In addition to testing the C1 domain, consisting only of the CRA
domain, we took advantage of this relatively simple system to also test the N2
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Figure 3.5. ΔC1 RanBPM is unable to interact effectively with ΔN c-Raf. HeLa 27 cells were transfected with either pEBG-GST and pCMV-HA-RanBPM or pEBGGST-ΔN-c-Raf and either pCMV-HA-RanBPM or a pCMV-HA RanBPM deletion
mutant. A GST pull-down assay was performed on the resulting extracts and pulldowns were analyzed by Western blot. (A,B) Representative images are shown. (C)
Multiple experiments were quantified by normalizing RanBPM mutant levels to
pulled-down GST or GST-ΔN-c-Raf and statistical analyses were performed (N 4–9,
SEM shown).
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Figure 3.6. Full-length RanBPM and individual domains chosen for analysis.
WT RanBPM, N2 domain and C1 domain were cloned into the bacterial expression
vector pGEX-4T-1.
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domain, which remained unexamined due to the poor level of expression of the
ΔN2 RanBPM deletion mutant in previously conducted mammalian cell-based
GST pull-down assays (Figure 3.5).
Each GST-tagged construct, as well as GST alone, was expressed
separately in E. coli and purified using Glutathione-Agarose beads. These
constructs were each subsequently incubated with a crude cell lysate from E. coli
expressing ΔN c-Raf. The GST-tagged constructs were pulled-down and
analyzed by Western blot to detect levels of associated ΔN c-Raf.
Both GST-WT-RanBPM and GST-C1 were able to pull-down ΔN c-Raf
significantly above background levels pulled down by GST alone, demonstrating
5.02 ± 0.98 and 2.71 ± 0.36 fold increases, respectively (Figures 3.7A and 3.7B).
Although it appears that WT RanBPM associates with ΔN c-Raf better than the
C1 domain does, the variability within the levels of ΔN c-Raf pulled-down with
WT RanBPM was relatively high and in fact the amount of ΔN c-Raf pulled-down
with WT RanBPM is not significantly different than that pulled-down with the C1
domain (Figure 3.7B). Therefore, this result confirms that the CRA domain of
RanBPM is able to interact with c-Raf and the interaction between RanBPM and
c-Raf is direct.
GST-N2, unlike GST-WT-RanBPM and GST-C1, was unable to pull-down
ΔN c-Raf significantly better than GST alone (Figures 3.7A and 3.7B). This
suggests that the N-terminus of RanBPM is unable to directly interact with c-Raf,
although an indirect interaction cannot be ruled out based on these results.
3.5. Endogenous c-Raf and MAEA are found in a complex
Since only the CRA domain of RanBPM is able to interact with ΔN c-Raf
but multiple domains play a role in regulating its levels, it is likely that RanBPM is
interacting with another protein or complex in order to downregulate ΔN c-Raf. A
possible candidate is the CTLH complex, a potential E3 ubiquitin ligase complex
which has been shown to include RanBPM and could function to target c-Raf for
proteasomal degradation (46,47). For this reason, a PLA was performed to
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Figure 3.7. WT RanBPM and C1 domain interact directly with ΔN c-Raf. GST
pull-down assays were performed using GST, GST-WT-RanBPM, GST-N2-domain
and GST-C1-domain E. coli extracts as well as ΔN c-Raf E. coli extracts. Pull-downs
were analyzed by Western blot. (A) A representative image is shown. (B) Multiple
experiments were quantified by normalizing ΔN c-Raf levels to pulled-down GST,
GST-WT-RanBPM, GST-N2 or GST-C1 and statistical analyses were performed (N
6, SEM shown).
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investigate whether MAEA, a CTLH complex protein, is able to form a complex
with c-Raf.
As expected, interactions were not seen in the negative control, namely
HeLa cells in which primary antibodies were not added (Figure 3.8A). Since
MAEA and RanBPM are known to be found together within the CTLH complex
(42,46), a positive control was performed in HeLa cells using primary antibodies
against MAEA and RanBPM. Interactions were indeed seen in this positive
control (Figure 3.8B). In HeLa cells in which primary antibodies against MAEA
and c-Raf were added, interactions were observed, although in noticeably fewer
numbers than the positive control (Figure 3.8C). This evidence suggests that
endogenous c-Raf does form a complex with MAEA and could associate with the
CTLH complex as a whole.
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Figure 3.8. Endogenous MAEA and c-Raf are found in a complex. An in situ PLA
was performed in HeLa cells (A) without the addition of primary antibodies (negative
control), (B) using primary antibodies against MAEA and RanBPM (positive control)
and (C) using primary antibodies against MAEA and c-Raf. DAPI staining was used
to visualize the nuclei at 358nm, while the PLA dots representing protein-protein
interactions were visualized at 647nm.
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Chapter 4 – Discussion
4.1. Summary of findings
The aim of this study was to characterize the interaction between
RanBPM and c-Raf. We hypothesized that specific domains of RanBPM are
required for direct interaction with c-Raf and regulation of c-Raf stability by a
mechanism involving the CTLH complex. Specifically, we sought to determine
which domain(s) of RanBPM are required for regulation of c-Raf stability, identify
which domain(s) of RanBPM are required for interaction with c-Raf and
investigate the mechanism by which RanBPM downregulates c-Raf. In summary,
we found that RanBPM and c-Raf in fact do form a complex in cells. The Nterminus, CRA domain and LisH/CTLH domains of RanBPM are required for
downregulation of c-Raf but only the CRA domain is required for complex
formation with c-Raf (Table 4.1). RanBPM interacts directly with c-Raf and the
CRA domain is sufficient for this direct interaction to occur. Finally, the CTLH
complex member MAEA and c-Raf are also found together in a complex,
suggesting that c-Raf could associate not only with RanBPM and MAEA, but with
the entire CTLH complex.
4.2. Model and rationale
Based on the results obtained from this study, we propose a mechanism
by which RanBPM downregulates c-Raf (Figure 4.1). Since deletion of the CRA
domain of RanBPM was sufficient to abolish the interaction between RanBPM
and c-Raf and since the CRA domain alone was shown to be able to interact
directly with c-Raf, it has become evident that RanBPM interacts directly with cRaf through its CRA domain. Deletion of the CRA domain also prevented c-Raf
downregulation, presumably as c-Raf was no longer tethered to the protein
regulating its stability. Deletion of the LisH/CTLH domains also inhibited c-Raf
downregulation, however RanBPM still retained its ability to interact with c-Raf.
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Table 4.1. Summary of results of the effects of RanBPM constructs on
downregulation of ΔN c-Raf and interaction with ΔN c-Raf.

Downregulates ΔN c-Raf

Interacts with ΔN c-Raf

WT RanBPM

YES

YES

Δ212 RanBPM (ΔSPRY)

YES

YES

ΔC4 RanBPM (ΔC-terminus)

NO

NO

ΔC1 RanBPM (ΔCRA)

NO

NO

Δ360 RanBPM (ΔLisH/CTLH)

NO

YES

ΔN2 RanBPM (ΔN-terminus)

NO

ND

C1 domain (CRA)

ND

YES

N2 domain (N-terminus)

ND

NO

RanBPM construct

51

Figure 4.1. Model of the mechanism by which RanBPM downregulates c-Raf.
RanBPM directly interacts with c-Raf via its C-terminal CRA domain and presumably
interacts with another protein or protein complex, such as the CTLH complex, via its
LisH/CLTH domain to downregulate c-Raf.
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Therefore, it is hypothesized that some other protein or protein complex is
interacting with RanBPM through its LisH/CTLH domains to downregulate c-Raf.
Deletion of the N-terminus of RanBPM also resulted in a loss of c-Raf
downregulation and this region was also shown to be unable to interact directly
with c-Raf. Therefore, the N-terminus might aid the LisH/CTLH domains in
mediating the interaction between RanBPM and the unidentified complex
potentially responsible for downregulating c-Raf. This is plausible since the Nterminus is a potentially flexible proline-rich region of RanBPM which could fold
over to stabilize the protein or, in this case, stabilize interactions with other
proteins (16). Given that deletion of the SPRY domain did not perturb the ability
of RanBPM to downregulate or interact with c-Raf, we propose that this domain
does not participate in regulation of c-Raf.
We have presented a plausible mechanism which suggests the
involvement of an additional protein or protein complex in the downregulation of
c-Raf. We propose that c-Raf might be targeted for degradation by the CTLH
complex in a RanBPM-dependent manner, with c-Raf being tethered to the
complex by RanBPM through its CRA domain, and that the CTLH complex
interacts with RanBPM primarily through its LisH/CTLH domains. RanBPM is a
known member of the CTLH complex and our results show that c-Raf can
associate with both RanBPM and MAEA, another member of the CTLH complex.
This mammalian complex is comprised of six proteins in total, all of which have
known orthologs in S. cerevisiae that form the yeast Gid complex (6). Given that
the Gid complex is a proven E3 ubiquitin ligase, it has been hypothesized that
the CTLH complex may play a similar role in mammalian cells (6). Though this
has not experimentally been shown, we propose that the CTLH complex may
play a role in the ubiquitination and degradation of target proteins and that it may
be targeting c-Raf for degradation in a mechanism that depends on RanBPM as
a scaffold for the complex. While the topology of the mammalian CTLH complex
has not been elucidated, the idea that RanBPM may act as a scaffold in the
complex is consistent with previous studies. It has been shown that Gid1, the
yeast ortholog of RanBPM, acts as a scaffold for the Gid complex and interacts
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with other members of the complex mainly through its LisH and CTLH domains
(47).
Although the major piece of evidence in our study tying the CTLH complex
to c-Raf downregulation is the fact that c-Raf and MAEA associate in cells,
subtleties in our data are also consistent with the idea that the CTLH complex
may be involved in c-Raf downregulation. The number of interactions seen
between c-Raf and MAEA were noticeably fewer than the number of interactions
seen in the positive control between RanBPM and MAEA. This is compatible with
the idea that RanBPM and MAEA are fixed members of the CLTH complex,
whereas c-Raf may only associate with the complex temporarily to target it for
degradation. Also, previous studies in our laboratory have shown that RanBPM
has a greater effect on the active form of c-Raf, which represents only a fraction
of the total pool of endogenous c-Raf in the cell (24). This further supports the
observation that c-Raf associates with MAEA infrequently, as only activated cRaf may be targeted for degradation by RanBPM, MAEA and the rest of the
CTLH complex.
A large number of studies have described proteins that interact with
RanBPM, albeit they seldom provide functional significance for the interactions. A
number of these interacting proteins have been described in Chapter 1, but a
broader record has been retrieved from the BioGRID (Biological General
Repository for Interaction Datasets) version 3.2.114 (Figure 4.2) (105). In
addition to the evidence discussed in Chapter 1 of ARMc8, Rmnd5a and MAEA
being involved in ubiquitination, the collection of proteins retrieved from the
BioGRID that interact with RanBPM involved in ubiquitination, deubiquitination,
ubiquitin-like modification or management of ubiquitinated proteins give further
weight to the argument that RanBPM and the CTLH complex may play a role in
these processes.
For example, RanBPM has been shown to interact with the essential
aggresome component HDAC6 (histone deacetylase 6) (Figure 4.2) and our
laboratory has shown that RanBPM is essential for aggresome formation (103).
Aggresomes are perinuclear structures that accommodate ubiquitinated,
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Figure 4.2. RanBPM interactome retrieved from the BioGRID version 3.2.114
showing 71 proteins that interact with human RanBPM. Interactions between
RanBPM and other proteins are connected by a red line and interactions between
RanBPM interacting partners are connected by a blue line. CTLH complex members
are outlined in purple and proteins involved in ubiquitination, deubiquitination,
ubiquitin-like modification and management of ubiquitinated proteins are outlined in
green.
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misfolded or damaged proteins in conditions where the proteasome and the UPS
are overwhelmed (106). This crucial role in aggresome formation implies that
RanBPM has the ability to handle ubiquitinated proteins targeted for degradation.
In addition, RanBPM has been found to interact with the E3 ubiquitin ligase
TRAF6 (tumor necrosis factor-receptor-associated factor 6) (Figure 4.2) and to
reduce the TGF-β (transforming growth factor β) dependent auto-ubiquitination of
TRAF6 (107). Some high-throughput screens studying the ubiquitinome have
even found RanBPM among a pool enriched for ubiquitinated proteins (Figure
4.2) (108). This may simply be evidence of RanBPM itself being targeted for
ubiquitination, given that RanBPM has been shown to be ubiquitinated as well as
deubiquitinated specifically through interaction with USP11 (ubiquitin-specific
protease 11) (Figure 4.2) (109). However, there is still substantial reason to
suspect that RanBPM, in concert with the CTLH complex, could be playing a role
in protein ubiquitination and subsequent degradation by the proteasome.
Although we now propose the CTLH complex as the complex potentially
responsible for interacting with RanBPM to downregulate c-Raf, during the
course of this study we initially investigated other proteins and complexes which
we thought may be playing this role. Initially, we attempted to investigate Hsp90
as a potential c-Raf regulatory mechanism in this context. Hsp90 is a wellcharacterized molecular chaperone which has been shown to bind and stabilize
c-Raf, allowing it to properly participate in ERK pathway signaling (94-96). Since
previous results in our laboratory have shown that downregulation of c-Raf by
RanBPM inhibits further ERK pathway signaling and that RanBPM expression
disrupts complex formation between c-Raf and Hsp90, we hypothesized that
RanBPM might be preventing Hsp90 from stabilizing c-Raf (24). However, we
were unable to obtain further conclusive evidence of altered acetylation of
Hsp90, which reflects Hsp90 activity, in response to RanBPM expression (data
not shown). Furthermore, previous preliminary experiments in our laboratory
showed no evidence of E3 ubiquitin ligase CHIP complex formation with
RanBPM and c-Raf, suggesting CHIP is not involved in the downregulation of cRaf by RanBPM. Although other studies have shown that CHIP is able to
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ubiquitinate c-Raf and send it for proteasomal degradation, it has also been
suggested that c-Raf may be ubiquitinated and degraded by CHIP-independent
mechanisms (98-100).
4.3. Significance of the CRA domain as a binding-domain for c-Raf
Many studies have identified binding partners for RanBPM and suggested
roles for the protein in various cellular processes, but a clear function for
RanBPM has yet to be elucidated. Our study further contributes to our growing
knowledge of the protein and demonstrates the importance of the CRA domain of
RanBPM for its interaction with c-Raf. Some studies have already identified
certain regions of RanBPM to be required for interactions with specific proteins.
For example, the SPRY domain of RanBPM has been shown to be required for
interaction with CDK11p46, L1, MET, TrkA, AR and USP11 (7,8,20,25,35,109).
The SPRY domain, along with the LisH domain, has been shown to be sufficient
for interaction with BACE1, LRP and APP to increase Aβ generation (29). The
LisH and CTLH domains have both been shown to be required for RanBPM
interaction with HDAC6 and only FMRP has previously been shown to interact
with the CRA domain of RanBPM (14,103). Our study defines c-Raf as only the
second protein to be found to interact with RanBPM through the CRA domain
and further confirms this domain to be a protein interaction surface.
The CRA domain has only been reported in a small number of proteins
other than RanBPM, namely RanBP10 (Ran-binding protein 10), MAEA,
Rmnd5a, Rmnd5b and Twa1 (46,110). It has not been shown, but there is
potential for c-Raf to interact with the CRA domain of these proteins as well,
although most of these proteins are found within the CTLH complex. RanBP10,
the only non-CTLH complex member, shows very high sequence similarity to
RanBPM and has also been named for its supposed ability to interact with Ran
(110). The CRA domain has been predicted to contain six alpha-helices, and
thus has been hypothesized to resemble a DD superfamily domain (14). DD
superfamily proteins are generally proteins that propagate apoptotic signals, such
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as the death receptors p75NTR and Fas as well as a number of caspases (111).
Although c-Raf signaling affects the activities of many downstream proteins
involved in apoptosis, an extensive literature search did not reveal any c-Raf
interacting partners containing a DD superfamily domain. Thus, this study
appears to uncover a novel binding domain for c-Raf, as interacting partners
containing a CRA domain or a DD superfamily domain have not yet been
reported.
However, it is possible that c-Raf interacts specifically with a sub-section
of the CRA domain, such as with the surface of a particular helix, rather than with
the entire domain. c-Raf has in fact been shown to interact with the surface of
helices in other proteins. For example, residues lysine 49, arginine 56 and
arginine 60 along the surface of helix 3 in the protein 14-3-3 have been shown to
be important for interaction with c-Raf (112). Although residues on helices often
contribute the binding surface for protein-protein interactions, the details of the
direct interaction between c-Raf and the CRA domain remain to be examined.
4.4. Consequences of RanBPM-mediated regulation of c-Raf
This study also further contributes to our knowledge of c-Raf regulatory
mechanisms within mammalian cells. Although our evidence of RanBPMdependent CTLH complex downregulation of c-Raf is preliminary, the
consequences of this potential novel regulatory mechanism are impactful. As
previous work in our laboratory has shown, loss of c-Raf has serious downstream
signaling effects, as RanBPM-mediated downregulation of c-Raf and consequent
inhibition of the ERK pathway leads to decreased levels of the anti-apoptotic
proteins Bcl-2 and Bcl-XL (24). However, ERK1/2 has over 150 other
downstream signaling proteins and thus RanBPM-mediated destabilization of cRaf could affect any number of these signaling pathways and associated cellular
processes (54,66). c-Raf is also implicated in non-ERK pathway signaling, such
as its negative regulation of the pro-apoptotic proteins ASK1 and MST2 (72,73).
Though this has not been shown, RanBPM could partially exert its apoptotic

58

activity by protecting levels of ASK1 and MST2 through c-Raf downregulation.
Altogether, through multiple downstream effectors, c-Raf dictates a number of
cellular processes, such as differentiation, proliferation, motility and apoptosis
(54,55). Therefore its RanBPM-dependent regulation is a crucial factor in
ensuring these functions are properly executed.
c-Raf regulation has long been regarded as a target for cancer
therapeutics, since the ERK pathway is known to be upregulated in over onethird of all human cancers (56). Numerous drugs have been developed in an
attempt to combat Raf activity and increase tumour cell apoptosis, but drug
resistance remains an obstacle and combination drug therapy is often employed
to increase the chance of success. Given that RanBPM demonstrates tumour
suppressor activity, a RanBPM-derived cancer therapeutic could prove useful
and add diversity to the growing number of Raf inhibitors used in the clinic. In
addition to the previously mentioned work showing that RanBPM inhibits cell
survival and migration, preliminary data from our laboratory provides further
evidence of RanBPM as a crucial tumour suppressor (24). Immunocompromised
mice injected with RanBPM-deficient HEK cells showed significantly increased
tumour formation, primarily localized in the liver, compared to mice injected with
HEK cells expressing RanBPM (113). In addition, mouse embryonic fibroblasts
generated from RanBPM knockout mice bred in our laboratory showed increased
levels of c-Raf compared to those generated from WT mice (113). This provides
significant relevance to the concept of c-Raf regulation by RanBPM, as this event
has now been shown in a model that closely mimics human physiology.
4.5. Limitations of the study and future studies
Although the work presented in this thesis yielded informative results,
some limitations were encountered which could be taken into consideration when
planning future studies. Primarily, it was very difficult to obtain even expression of
RanBPM deletion mutants upon transfection in HeLa cells in order to fairly asses
the ability of each mutant to downregulate c-Raf. Given that RanBPM deletion
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mutants exhibit levels of stability different from one another, the amount of DNA
used for the transfection of each mutant construct had to be adjusted to obtain
similar levels of protein expression among all mutants. However, despite careful
optimization, the expression of RanBPM deletion mutants still varied somewhat.
Even expression might have been achieved with the generation of HeLa cell lines
stably expressing each RanBPM deletion mutant construct. This project remains
ongoing in the laboratory.
Furthermore, based on the presence or absence of NLS or NES signals
within the sequence of each RanBPM deletion mutant, the subcellular
localization of certain mutants could have been altered and hindered their ability
to downregulate c-Raf, a predominantly cytoplasmic protein. For example, both
Δ212 and Δ360 RanBPM demonstrate increased nuclear localization (16).
Therefore, 60–70% of the total protein is in fact sequestered within the nucleus
and unable to interact with c-Raf, although 30–40% is still nucleocytoplasmic and
able to participate in c-Raf regulation (16). Given that Δ212 RanBPM is mostly
nuclear but still demonstrates a strong ability to regulate c-Raf, it is presumed
that similar cytoplasmic levels of Δ360 RanBPM would have also demonstrated
this effect if the protein was fully functional in this aspect.
It is also important to note that large protein deletions can have a
significant negative impact on the proper folding and stability of a protein. This
phenomenon was exemplified perfectly in this study in the case of the ΔN2
RanBPM mutant, where deletion of the N-terminus of the protein resulted in
decreased expression, presumably due to protein instability. Although this type of
instability was not seen for the other RanBPM deletion mutants, it is difficult to
predict whether deletion of the SPRY domain, LisH/CTLH domains or C-terminus
resulted in misfolding of RanBPM. If this was the case, it would be impossible to
distinguish if the results obtained were in fact due to lack of a required functional
domain or simply due to misfolding of the protein. Generating point mutations
inhibiting the function of a specific domain is generally a more cautious approach
when conducting these types of studies, however given a lack of knowledge on
the key residues within each domain of RanBPM, this strategy could not be
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employed here. However, future studies could focus on locating specific residues
within the CRA domain of RanBPM that abolish its interaction with c-Raf.
Subsequent experiments using this mutant could give a more reliable idea of the
effect of loss of interaction between RanBPM and c-Raf, since RanBPM folding
would be less likely to be affected by a simple point mutation.
Other key future studies include continuing to explore the idea of CTLH
complex involvement in RanBPM-mediated c-Raf downregulation. It would be
important to provide evidence of RanBPM-dependent c-Raf ubiquitination or
proteasomal degradation, although this was attempted during the course of this
study and no conclusive evidence was obtained (data not shown). It would also
be intriguing to knock-down expression of various CTLH complex members in
cells and investigate the effect on c-Raf. Since shRNA knock-down of RanBPM
leads to increased levels of c-Raf, knocking-down a CTLH complex member
would be expected to yield similar results. Altogether, this would further support
the hypothesis that the CTLH complex is involved in c-Raf regulation.
4.6. Conclusion
Overall, this thesis aimed to characterize the interaction between two
important regulators of key cellular processes, RanBPM and c-Raf. Although the
role and importance of c-Raf has been well-documented in the past, the exact
function of RanBPM remains an enigma and ongoing research in the fields of
cancer and neurological disease aims to better understand this protein. The work
presented in this thesis not only contributes to our knowledge of RanBPM, but
also clarifies the relationship between RanBPM and c-Raf by proposing a novel
model regarding how RanBPM downregulates c-Raf. Such knowledge is critical
in understanding RanBPM as a tumour suppressor and regulator of the ERK
pathway, a pathway known to be heavily involved in human oncogenesis.
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